Identification of oncogenic point mutations and hyperphosphorylation of anaplastic lymphoma kinase in lung cancer

Neoplasia

Volumn 13, Issue 8, 2011, Pages 704-715

  Wang, Yi Wei ^a,b   Tu, Pang Hsien ^a,b   Lin, Kuen Tyng ^b   Lin, Shu Chen ^b   Ko, Jenq Yuh ^c   Jou, Yuh Shan ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT3 PROTEIN;

ADULT; AGED; ALK GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENICITY; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 80051492649     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11222     Document Type: Article

References (47)

1. World Health Organization. Cancer. Geneva, Switzerland: World Health Organization. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/. Fact sheet N°297, February 2011.
2. Ladanyi M and Pao W (2008). Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 21(suppl 2), S16-S22.
3. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, et al. (2005). Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65, 1479-1488.
4. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, et al. (2004). Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525-526.
5. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500.
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139.
7. [Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, and Minna JD (1989). p53: a frequent target for genetic abnormalities in lung cancer. Science 246, 491-494.
8. Santos E, Martin-Zanca D, Reddy EP, Pierotti MA, Della Porta G, and Barbacid M (1984). Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 223, 661-664.
9. Samuels Y and Velculescu VE (2004). Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3, 1221-1224.
10. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al. (2004). High frequency of mutations of the PIK3- CA gene in human cancers. Science 304, 554.
11. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, and Meyerson M (2002). Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 62, 7001-7003.
12. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, et al. (2002). BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62, 6997-7000.
13. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, Westra WH, Herman JG, and Sidransky D (2002). Inactivation of LKB1/ STK11 is a common event in adenocarcinomas of the lung. Cancer Res 62, 3659-3662.
14. Subramanian J and Govindan R (2008). Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol 9, 676-682.
15. Sun S, Schiller JH, and Gazdar AF (2007). Lung cancer in never smokers-a different disease. Nat Rev Cancer 7, 778-790.
16. Herbst RS, Heymach JV, and Lippman SM (2008). Lung cancer. N Engl J Med 359, 1367-1380.
17. Sun S, Schiller JH, Spinola M, and Minna JD (2007). New molecularly targeted therapies for lung cancer. J Clin Invest 117, 2740-2750.
18. Jemal A, Siegel R, Ward E, Hao Y, Xu J, and Thun MJ (2009). Cancer statistics, 2009. CA Cancer J Clin 59, 225-249.
19. Fischer P, Nacheva E, Mason DY, Sherrington PD, Hoyle C, Hayhoe FG, and Karpas A (1988). A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor ß-chain gene. Blood 72, 234-240.
20. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, and Look AT (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281-1284.
21. Chiarle R, Voena C, Ambrogio C, Piva R, and Inghirami G (2008). The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8, 11-23.
22. Horn L and Pao W (2009). EML4-ALK: honing in on a new target in non- small-cell lung cancer. J Clin Oncol 27, 4232-4235.
23. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566.
24. Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, Haruta H, Hamada T, Yamashita Y, Ishikawa Y, et al. (2008). A mouse model for EML4- ALK-positive lung cancer. Proc Natl Acad Sci USA 105, 19893-19897.
25. Li Y, Ye X, Liu J, Zha J, and Pei L (2011). Evaluation of EML4-ALKfusion proteins in non-small cell lung cancer using small molecule inhibitors. Neoplasia 13, 1-11.
26. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075.
27. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, et al. (2010). EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363, 1734-1739.
28. Palmer RH, Vernersson E, Grabbe C, and Hallberg B (2009). Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 420, 345-361.
29. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T, et al. (2008). Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974.
30. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, et al. (2008). Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970.
31. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, et al. (2008). Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935.
32. George RE, Sanda T, Hanna M, Frohling S, Luther W II, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, et al. (2008). Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978.
33. Tseng RC, Chang JW, Hsien FJ, Chang YH, Hsiao CF, Chen JT, Chen CY, Jou YS, and Wang YC (2005). Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer. Int J Cancer 117, 241-247.
34. Lamant L, Pulford K, Bischof D, Morris SW, Mason DY, Delsol G, and Mariame B (2000). Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 156, 1711-1721.
35. Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, and Wasik MA (2007). Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene 26, 5606-5614.
36. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J, et al. (2007). Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 104, 270-275.
37. Balsara BR and Testa JR (2002). Chromosomal imbalances in human lung cancer. Oncogene 21, 6877-6883.
38. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, et al. (2007). Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893-898.
39. Yuan J, Ma J, Zheng H, Shi T, Sun W, Zhang Q, Lin D, Zhang K, He J, Mao Y, et al. (2008). Overexpression of OLC1, cigarette smoke, and human lung tumorigenesis. J Natl Cancer Inst 100, 1592-1605.
40. Tsai MF, Wang CC, Chang GC, Chen CY, Chen HY, Cheng CL, Yang YP, Wu CY, Shih FY, Liu CC, et al. (2006). A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma. J Natl Cancer Inst 98, 825-838.
41. Marzec M, Kasprzycka M, Ptasznik A, Wlodarski P, Zhang Q, Odum N, and Wasik MA (2005). Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Invest 85, 1544-1554.
42. Colomba A, Courilleau D, Ramel D, Billadeau DD, Espinos E, Delsol G, Payrastre B, and Gaits-Iacovoni F (2008). Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas. Oncogene 27, 2728-2736.
43. Boland JM, Erdogan S, Vasmatzis G, Yang P, Tillmans LS, Johnson MR, Wang X, Peterson LM, Halling KC, Oliveira AM, et al. (2009). Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 40, 1152-1158.
44. Martelli MP, Sozzi G, Hernandez L, Pettirossi V, Navarro A, Conte D, Gasparini P, Perrone F, Modena P, Pastorino U, et al. (2009). EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 174, 661-670.
45. Pulford K, Lamant L, Morris SW, Butler LH, Wood KM, Stroud D, Delsol G, and Mason DY (1997). Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89, 1394-1404.
46. Corao DA, Biegel JA, Coffin CM, Barr FG, Wainwright LM, Ernst LM, Choi JK, Zhang PJ, and Pawel BR (2009). ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status. Pediatr Dev Pathol 12, 275-283.
47. Bossi RT, Saccardo MB, Ardini E, Menichincheri M, Rusconi L, Magnaghi P, Orsini P, Avanzi N, Borgia AL, Nesi M, et al. (2010). Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 49, 6813-6825.